Abbreviations:AUA (American Urologic Association), BTX (intradetrusor chemodenervation with onabotulinum toxin A), CCAE (Commercial Claims and Encounters), CPT (Current Procedural Terminology), FDA (Food and Drug Administration), ICD (International Classification of Disease), IRB (Institutional Review Board), OAB (overactive bladder), PTNS (percutaneous tibial nerve stimulation), SNM (sacral neuromodulation), SUFU (society of urodynamics, female pelvic medicine & urogenital reconstruction)
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction.Neurourol Urodyn. 2010; 29: 4https://doi.org/10.1002/nau.20798
- Treatment of overactive bladder in women.Evid Rep Technol Assess (Full Rep). 2009; 187: 94
- Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019.J Urol. 2019; 202: 558https://doi.org/10.1097/JU.0000000000000309
- Comparative Effectiveness of Anticholinergic Therapy for Overactive Bladder in Women.Obstet Gynecol. 2015; 125: 1423https://doi.org/10.1097/AOG.0000000000000851
- Development and Validation of a Machine Learning Algorithm for Predicting Response to Anticholinergic Medications for Overactive Bladder Syndrome.Obstet Gynecol. 2019; 134: 946https://doi.org/10.1097/AOG.0000000000003517
Premarket Approval Database: Interstim. Food and Drug Administration Web Site. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P970004. Accessed October 8, 2021.
510(k) Premarket Notification Database: NURO Neuromodulation System. Food and Drug Administration Web Site. https://www.accessdata.fda.gov/cdrh_docs/pdf10/K101847.pdf. Accessed October 8, 2021.
- Treatment of neurogenic incontinence with botulinum toxin A.N Engl J Med. 2000; 342: 665https://doi.org/10.1056/NEJM200003023420918
Drug Databases: FDA-Approved Drugs: BOTOX. Food and Drug Administration Web Site. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103000. Accessed October 8, 2021.
Butler AM, Nickel KB, Overman RA, et al: IBM MarketScan Research databases. In Databases for Pharmacoepidemiological Research. Sturkenboom M and Schink T. Springer, Cham 2021; 1: 243–251.
Watson Health IBM Corporation 2021. IBM MarketScan Research Databases for Life Sciences Researchers. https://www.ibm.com/products/marketscan-research-databases/databases. Accessed April 20, 2022.
- Real World Performance of Sacral Neuromodulation and OnabotulinumtoxinA for Overactive Bladder: Focus on Safety and Cost.J Urol. 2020; 203: 179https://doi.org/10.1097/JU.0000000000000462
- National Patterns of Filled Prescriptions and Third-Line Treatment Utilization for Privately Insured Women With Overactive Bladder.Female Pelvic Med Reconstr Surg. 2021; 27: e261https://doi.org/10.1097/SPV.0000000000000744
- Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States.Neurourol Urodyn. 2018; 37: 213https://doi.org/10.1002/nau.23276
Glossary. United States Census Bureau Web Site. https://www.census.gov/programs-surveys/metro-micro/about/glossary.html. Accessed August 11, 2022.
- Why Patients Fall Through the Cracks: Assessment of Patients' Overactive Bladder Treatment.J Womens Health (Larchmt). 2022; 31: 1314https://doi.org/10.1089/jwh.2021.0635
- National Trends in the Surgical Management of Urinary Incontinence among Insured Women, 2004 to 2013: The Urologic Diseases in America Project.J Urol. 2020; 203: 365https://doi.org/10.1097/JU.0000000000000569
- Disparities in the use of sacral neuromodulation among Medicare beneficiaries.J Urol. 2015; 194: 449https://doi.org/10.1016/j.juro.2015.03.111
- Contemporary Patterns of Third-line Treatments for Privately Insured Individuals With Overactive Bladder in the United States.Urology. 2020; 142: 87https://doi.org/10.1016/j.urology.2020.04.102
- Trend in rural-urban disparities in access to outpatient mental health services among US adults aged 18-64 with employer-sponsored insurance: 2005-2018.J Rural Health. 2022; 38: 788https://doi.org/10.1111/jrh.12644
- Rural-urban disparities in health care costs and health service utilization following pediatric mild traumatic brain injury.Health Serv Res. 2019; 54: 337https://doi.org/10.1111/1475-6773.13096
- A systematic review of racial/ethnic disparities in female pelvic floor disorders.Urology. 2022; 163: 8https://doi.org/10.1016/j.urology.2021.09.018
- The effect of social determinants of health on overactive bladder symptom severity.J Urol. 2021; 205: 1415https://doi.org/10.1097/JU.0000000000001545
- Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-Month Results of the ARTISAN-SNM Study.J Urol. 2020; 203: 185https://doi.org/10.1097/JU.0000000000000458
- Feasibility of a Fully Implanted, Nickel Sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence.J Urol. 2019; 201: 967https://doi.org/10.1016/j.juro.2018.10.017
- Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study.JAMA Intern Med. 2015; 175: 401https://doi.org/10.1001/jamainternmed.2014.7663
- Alzheimer's Disease Neuroimaging Initiative. Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults.JAMA Neurol. 2016; 73: 721https://doi.org/10.1001/jamaneurol.2016.0580
Publication stageIn Press Journal Pre-Proof
Declaration of interests: None